Epidemiology of contralateral breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 8, Issue 10, 1999, Pages 855-861

  Chen, Yue ^a   Thompson, Wendy ^a   Semenciw, Robert ^b   Mao, Yang ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b LAB CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BODY WEIGHT; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; ENDOMETRIUM CANCER; FAMILY HISTORY; FEMALE; HUMAN; ONSET AGE; PRIORITY JOURNAL; REPRODUCTION; REVIEW; RISK FACTOR; SECOND CANCER;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; NEOPLASMS, MULTIPLE PRIMARY; PROGNOSIS; RISK FACTORS;

EID: 0032709966     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Horn-Ross, P. L. Multiple primary cancers involving the breast. Epidemiol. Rev., 15: 169-176, 1993.
2. Kilgore, A. R. The incidence of cancer in the second breast. J. Am. Med. Assoc., 77: 454-457, 1921.
3. Horn, P. L., and Thompson, W. D. Risk of contralateral breast cancer: associations with factors related to initial breast cancer. Am. J. Epidemiol., 128: 309-323, 1988.
4. Thompson, W. D. Methodologic perspectives on the study of multiple primary cancers. Yale J. Biol. Med., 59: 505-516, 1986.
5. Robbins, G. F., and Berg, J. W. Bilateral primary breast cancers: a prospective clinicopathological study. Cancer (Phila.), 17: 1501-1527, 1964.
6. Lewison, E. F., and Neto, A. S. Bilateral breast cancer at the Johns Hopkins Hospital: a discussion of the dilemma of contralateral breast cancer. Cancer (Phila.), 28: 1297-1301, 1971.
7. Schottenfeld, D. Multiple primary cancers. In: D. Schottenfeld and J. F. Fraumen Jr. (eds.), Cancer Epidemiology and Prevention, Ed. 2, pp. 1370-1381. New York: Oxford University Press, 1996.
8. Haagensen, C. D. Diseases of the Breast, Ed. 2, pp. 449-458. Philadelphia: W. B. Saunders Co., 1971.
9. Schottenfeld, D., and Berg, J. Incidence of multiple primary cancers. IV. Cancers of the female breast and genital organs. J. Natl. Cancer Inst., 46: 161-170, 1971.
10. Prior, P., and Waterhouse, J. A. H. Incidence of bilateral tumours in a population-based series of breast-cancer patients. I. Two approaches to an epidemiological analysis. Br. J. Cancer, 37: 620-634, 1978.
11. Mueller, C. B., and Ames, F. Bilateral carcinoma of the breast: frequency and mortality. Can. J. Surg., 21: 459-465, 1978.
12. Hankey, B. F., Curtis, R. E., Naughton, M. D., Boice, J. D., Jr., and Flannery, J. T. A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy. J. Natl. Cancer Inst., 70: 797-804, 1983.
13. Burns, P. E., Dabbs, K., May, C., Lees, A. W., Birkett, L. R., Jenkins, H. J., and Hanson, J. Bilateral breast cancer in Northern Alberta: risk factors and survival patterns. Can. Med. Assoc. J., 130: 881-886, 1984.
14. Chaudary, M. A., Millis, R. R., Hoskins, E. O., Halder, M., Bulbrook, R. D., Cuzick, J., and Hayward, J. L. Bilateral primary breast cancer: a prospective study of disease incidence. Br. J. Surg., 71: 711-714, 1984.
15. Hislop, T. G., Elwood, J. M., Coldman, A. J., Spinelli, J. J., Worth, A. J., and Ellison, L. G. Second primary cancers of the breast: incidence and risk factors. Br. J. Cancer, 49: 79-85, 1984.
16. Harvey, E. B., and Brinton, L. A. Second cancer following cancer of the breast in Connecticut, 1935-1982. Natl. Cancer Inst. Monogr., 68: 99-112, 1985.
17. Storm, H. H., and Jensen, O. M. Risk of contralateral breast cancer in Denmark, 1943-1980. Br. J. Cancer, 54: 483-492, 1986.
18. Murakami, R., Hiyama, T., Hanai, A., and Fujimoto, I. Second primary cancers following female breast cancer in Osaka. Japan: a population-based cohort study. Jpn. J. Clin. Oncol., 17: 293-302, 1987.
19. Rosen, P. P., Groshen, S., Kinne, D. W., and Hellman, S. Contralateral breast carcinoma: an assessment of risk and prognosis in Stage I (T1N0M0) and Stage II (T1N1M0) patients with 20-year follow-up. Surgery, 106: 904-910, 1989.
20. Brenner, H., Siegle, S., Stegmaier, C., and Ziegler, H. Second primary neoplasms following breast cancer in Saarland, Germany, 1968-1987. Eur. J. Cancer, 29A: 1410-1414, 1993.
21. Healey, E. A., Cook, E. F., Orav, E. J., Schnitt, S. J., Connolly, J. L., and Harris, J. R. Contralateral breast cancer: clinical characteristics and impact on prognosis. J. Clin. Oncol., 11: 1545-1552, 1993.
22. Volk, N., and Pompe-Kim, V. Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control, 8: 764-770, 1997.
23. McCredie, J. A., Inch, W. R., and Alderson, M. Consecutive primary carcinomas of the breast. Cancer (Phila.), 35: 1472-1477, 1975.
24. Fisher, E. R., Fisher, B., Sass, R., Wickerham. L., and Collaborating NSABP Investigators. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No.4). XI. Bilateral breast cancer. Cancer (Phila.), 54: 3002-3011, 1984.
25. Kurtz, J. M., Amalric, R., Brandone, H., Ayme, Y., and Spitalier, J-M. Contralateral breast cancer and other second malignancies in patients treated by breast-conserving therapy with radiation. Int. J. Radiat. Oncol. Biol. Phys., 15: 277-284, 1988.
26. Cook, L. S., White, E., Schwartz, S. M., McKnight, B., Daling, J. R., and Weiss, N. S. A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States). Cancer Causes Control, 7: 382-390, 1996.
27. Kato, I., Miura, S., Yoshida, M., and Tominaga, S. Risk factors of multiple primary cancers in breast cancer patients. Jpn. J. Cancer Res., 77: 296-304, 1986.
28. Bernstein, J. L., Thompson, W. D., Risch, N., and Holford, T. R. The genetic epidemiology of second primary breast cancer. Am. J. Epidemiol., 136: 937-948, 1992.
29. Boice, J. D., Jr., Harvey, E. B., Blettner, M., Stovall, M., and Flannery, J. T. Cancer in the contralateral breast after radiotherapy for breast cancer. N. Engl. J. Med., 326: 781-785, 1992.
30. Storm, H. H., Andersson, M., Boice, J. D., Jr., Blettner, M., Stovall, M., Mouridsen, H. T., Dombernowsky, P., Rose, C., Jacobsen, A., and Pedersen. M. Adjuvant radiotherapy and risk of contralateral breast cancer. J. Natl. Cancer Inst., 84: 1245-1250, 1992.
31. Anderson, D. E., and Badzioch, M. D. Bilaterality in familial breast cancer patients. Cancer (Phila.), 56. 2092-2098, 1985.
32. Horn, P. L., Thompson, W. D., and Schwartz, S. M. Factors associated with the risk of second primary breast cancer: an analysis of data from the Connecticut Tumor Registry. J. Chronic Dis., 40: 1003-1011, 1987.
33. Broet, P., de la Rochefordiere, A., Scholl, S. M., Fourquet, A., Mosseri, V., Durand, J-C., Pouillart, P., and Asselain, B. Contralateral breast cancer: annual incidence and risk parameters. J. Clin. Oncol., 13: 1578-1583, 1995.
34. Adami, H-O., Hansen, J., Jung, B., Lindgren, A., and Rimsten, A. Bilateral carcinoma of the breast: epidemiology and histopathoiogy. Acta. Radiol. Oncol., 20: 305-309, 1981.
35. Webber, B. L., Heise, H., Neifeld, J. P., and Costa, J. Risk of subsequent contralateral breast carcinoma in a population of patients with in-situ breast carcinoma. Cancer (Phila.), 47: 2928-2932, 1981.
36. Horn, P. L., and Thompson, W. D. Risk of contralateral breast cancer: associations with histologic, clinical and therapeutic factors. Cancer (Phila.), 62: 412-424, 1988.
37. Bernstein, J. L., Thompson, W. D., Risch, N., and Holford, T. R. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am. J. Epidemiol., 136: 925-936, 1992.
38. Dixon, J. M., Anderson, T. J., Page, D. L., Lee, D., Duff, S. W., and Stewart, H. J. Infiltrating lobular carcinoma of the breast: an evaluation of the incidence and consequence of bilateral disease. Br. J. Surg., 70: 513-516, 1983.
39. Habel, L. A., Moe, R. E., Daling, J. R., Holte, S., Rossing, M. A., and Weiss, N. S. Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann. Surg., 225: 69-75, 1997.
40. Basco, V. E., Coldman, A. J., Elwood, J. M., and Young, M. E. J. Radiation dose and second breast cancer. Br. J. Cancer, 52: 319-325, 1985.
41. Parker, R. G., Grimm, P., and Enstrom, J. E. Contralateral breast cancers following treatment for initial breast cancers in women. Am. J. Clin. Oncol., 12: 213-216, 1989.
42. Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., Margolese, R., Robidoux, A., Shibata, H., Terz, J., Paterson, A. H. G., Feldman, M. I., Farrar, W., Evans, J., Lickley, H. L., Ketner, M., et al. A randomized clinical trial evaluating Tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med., 320: 479-484, 1989.
43. Lavey, R. S., Eby, N. L., and Prosnitz, L. R. Impact of radiation therapy and/or chemotherapy on the risk for a second malignancy after breast cancer. Cancer (Phila.), 66: 874-881, 1990.
44. Horn, P. L., and Thompson, W. D. Exposure to chemotherapeutic agents and the risk of a second breast cancer: preliminary findings. Yale J. Biol. Med., 61: 223-231, 1988.
45. Arriagada, R., and Rutqvist, L. E. Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies. Lancet, 338: 535-538, 1991.
46. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet, 339: 1-15, 71-85, 1992.
47. Rutqvist, L. E., Cedermark, B., Glas, U., Mattsson, A., Skoog, L., Somell, A., Theve, T., Wilking, N., Askergren, J., Hjalmar, M-L., Rotstein, S., Perbeck, L., and Ringborg, U. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J. Natl. Cancer Inst., 83: 1299-1306, 1991.
48. Stewart, H. J. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. J. Natl. Cancer Inst. Monogr., 11: 117-120, 1992.
49. Cancer Research Campaign Breast Cancer Trials Group. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Eur. J. Cancer, 28A: 904-907, 1992.
50. Fornander, T., Rutqvist, L. E., Cedermark, B., Glas, U., Mattsson, A., Silfversward, C., Skoog, L., Somell, A., Theve, T., Wilking, N., Askergren, J., and Hjalmar, M-L. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet, 1: 117-120, 1989.
51. Rutqvist, L. E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T., and Wilking, N. Adjuvant tamoxifen therapy for early-stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J. Natl. Cancer. Inst., 87: 645-651, 1995.
52. Cook, L. S., Weiss, N. S., Schwartz, S. M., White, E., McKnight, B., Moore, D. E., and Daling, J. R. Population-based study of tamoxifen therapy and sub-sequent ovarian, endometrial and breast cancers. J. Natl. Cancer. Inst., 87: 1359-1364, 1995.
53. Andersson, M., Storm, H. H., and Mouridsen, H. T. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J. Natl. Cancer Inst., 83: 1013-1017, 1991.
54. Adami, H-O., Bergstrom, R., and Hansen, J. Age at first primary as a determinant of the incidence of bilateral breast cancer: cumulative and relative risks in a population-based case-control study. Cancer (Phila.), 55: 643-647, 1985.
55. Haagensen, C. D., Bodian, C., and Haagensen, D. E. Breast Carcinoma: Risk and Detection, pp. 339-364. Philadelphia: W. B. Saunders Co., 1981.
56. Sakamoto, G., Sugano, H., and Kasumi, F. Bilateral breast cancer and familial aggregations. Prev. Med., 7: 225-229, 1978.
57. Schwartz, A. G., Ragheb, N. E., and Swanson, G. M. Race and age differences in multiple primary cancers after breast cancer: a population-based analysis. Breast Cancer Res. Treat., 14: 245-254, 1989.
58. Boice, J. D., Jr., Connecticut Tumor Registry, and Cancerregisteret (Denmark) (eds). Multiple Primary Cancers in Connecticut and Denmark. National Cancer Institute Monograph Number 68. NIH Publication Number 85-2714. Bethesda, MD: National Cancer Institute, 1985.